Pre-IPO RemeGen - Insights on Two Core Products RC18 & RC48
This article analyzed two core products from RemeGen: RC18 and RC 48. The commercialization of these two products would have direct impact on the...
414 Views
India ECM 2020 Mid-Year Review - A Year of Secondary and Rights Issues
Its been a quiet year for listings for most of Asia-Pacific with only Hong Kong being a more recent exception. To say that its been a quite year...
445 Views
SK Biopharm IPO Industry Analysis & Contract Details
In this insight, we provide further details on the SK Biopharmaceuticals (BIO SK) IPO, including the industry and competitive analysis. We have...
227 Views
ECM Weekly (10 May 2020) - Kingsoft Cloud, NetEase, Central China New Life, Peijia Medical, Kintor,
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. As...
333 Views
Hindustan Unilever Placement - As Expected, Doing It Right
In my insight earlier this week, Hindustan Unilever Prospective Placement - Early Look - The US$3.6bn Overhang, I wrote about how GlaxoSmithKline...
416 Views